Advertisement

A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: A gynecologic oncology group study

      This paper is only available as a PDF. To read, Please Download here.
      In this study, 331 patients with advanced or recurrent squamous cell carcinoma of the cervix no longer amenable to control with surgery or radiotherapy were randomized to receive cisplatin 50 mg/m2 as either a continuous infusion over 24 hr or a more rapid infusion at a rate of 1 mg/min. Antiemetic therapy was standardized for the initial course of both regimens as metoclopramide 60 mg at the time of and at 3 and 6 hours after initiation of cisplatin. The overall frequency of objective regression of disease was 18%; the response rate in each regimen was essentially identical. The continuous infusion regimen was associated with a significantly greater percentage of patients who experienced no nausea and vomiting (34% versus 18%, P = 0.002). Other adverse effects included nephrotoxicity, peripheral neuropathy, myelosuppression, and ototoxicity. Both the frequency and severity of these were essentially the same for each regimen.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Thigpen T.
        • Shingleton H.
        • Homesley H.
        • et al.
        cis-Platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group.
        Cancer. 1981; 48: 899-903
        • Bonomi P.
        • Blessing J.
        • Stehman F.
        • et al.
        Randomized trial of three cisplatin dose schedules in squamous cell carcinoma of the cervix (a Gynecologic Oncology Group Study).
        J. Clin. Oncol. 1985; 3: 1079-1085
        • Blessing J.A.
        Design, analysis and interpretation of chemotherapy trials in gynecologic cancer.
        in: Deppe G. Chemotherapy of gynecologic cancer. A. R. Liss, New York1984: 49-83
        • DeVita Jr., V.
        • Wasserman T.
        • Young R.
        • et al.
        Perspectives and research in gynecologic oncology.
        Cancer. 1976; 38: 509
        • Thigpen T.
        • Vance R.
        • Balducci L.
        • Blessing J.
        Chemotherapy in the management of advanced or recurrent cervical and endometrial carcinoma.
        Cancer. 1981; 48: 658
        • Jacobs C.
        • Bertino J.
        • Goffinet D.
        • et al.
        24-hour infusion of cis-platinum in head and neck cancers.
        Cancer. 1978; 42: 2135-2140
        • Salem P.
        • Hall S.
        • Benjamin R.
        • et al.
        Clinical phase I–II study of cis-dichloro-diammineplatinum (II) given by continuous IV infusion.
        Cancer Treat. Rep. 1978; 62: 1553-1555
        • Gralla R.
        • Itri L.
        • Pisko S.
        • et al.
        Antiemetic efficacy of high-dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting.
        N. Engl. J. Med. 1981; 305: 905-909
      1. Lewis, G. Personal communication.

        • Drewinko B.
        • Brown B.
        • Gottlieb J.
        The effect of cis-diamminedichloroplatinum (II) on cultured human lymphoma cells and its therapeutic implications.
        Cancer Res. 1973; 33: 3091-3095
        • Gullo J.
        • Litterst C.L.
        • Macguire P.J.
        • et al.
        Pharmacokinetics and protein binding of cis-dichlorodiammineplatinum (II) administered as a one-hour or as a 20-hour infusion.
        Cancer Pharmacol. 1980; 5: 21-26